Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618092 | 0.82 | MAPT (0.54) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 | |
| SCHEMBL4058670 | 0.81 | CNR1 (0.48) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 | |
| SCHEMBL9597948 | 0.81 | RAB9A (0.55) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 | |
| SCHEMBL4057593 | 0.80 | KMT2A (0.53) | — | |
| SCHEMBL4055666 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 | |
| SCHEMBL620485 | 0.77 | GABRP (0.66) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 | |
| SCHEMBL4056213 | 0.77 | ALDH1A1 (0.48) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 | |
| SCHEMBL4055673 | 0.77 | CDKN1A (0.52) | LMNAALDH1A1POLB | |
| SCHEMBL27709659 | 0.76 | ABCC1 (0.48) | KDM4ELMNAALDH1A1BLMMAPT | |
| SCHEMBL4065547 | 0.76 | KMT2A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | claimed |
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | GABBR1, CHRNA5, CHRNA3 | SMN1; SMN2 219/4885KDM4E 1637/4885LMNA 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.